Brief: Laurus Labs Says USFDA Completes Inspection Of Facilities At Anakapalli
19/04/2024 13:40
April 19 (Reuters) - Laurus Labs Ltd LAUL.NS :
* USFDA COMPLETED INSPECTION OF OUR API MANUFACTURING
FACILITIES
UNIT–1 AND UNIT–3,ANAKAPALLI
* THE INSPECTION WAS SUCCESSFULLY CLOSED WITHOUT ANY 483
OBSERVATIONS
Source text for Eikon: ID:
Further company coverage: LAUL.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Laurus Labs
See all newsIndia's Laurus Labs hits record high as Q2 profit more than doubles
Brief: Laurus Labs Declares Dividend Of 1 Rupee Per Share
Brief: Laurus Labs Invests 1.08 Billion Rupees Into KRKA Pharma Via Rights Issue
Brief: Laurus Labs Invests 120.96 Million Rupees In Kurnool Renewables Via Rights Issue
Four Indian stocks to be added, three removed from key global index in MSCI's August rejig